Nurix Therapeutics, Inc. (NRIX)
NRIXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$16.14
+0.8400 (+5.49%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.76bn
- P/E
- 7.0
- EPS, last 4 quarters
- $2.31
- Dividend yield
- –
- Day range
- –
- 52-week range
- $11.67 to $28.23
- Average volume
- 2.46m
- Previous close
- $15.30
Analysts
11 coveringBuy9 buy, 2 hold, 0 sell
Targets a year out average $33.80, +109.4% from here
Earnings
next estimate $-0.4600Next report
Nov 2025
+2.4%
Feb 2026
-4.0%
May 2026
-11.0%
Aug 2026
+944.6%
estimate reported, and the surprise
Financials
| Quarter | Nov 2025 | Feb 2026 | May 2026 | Aug 2026 |
|---|---|---|---|---|
| Revenue | $13.58m | $6.25m | $9.04m | $673.06m |
| Gross profit | $13.58m | $6.25m | $9.04m | $673.06m |
| Operating income | -$83.09m | -$92.50m | -$94.20m | $559.45m |
| Net income | -$78.22m | -$87.17m | -$89.53m | $549.81m |
Last four quarters: revenue $701.94m, margin 42.0%, free cash flow $369.81m
News
8 latest- Nurix Shares Fall 40% After Sanofi Discontinues STAT6 Degrader Program RTTNews · 5 days ago
- Nurix Therapeutics, Inc. Announces Sanofi Discontinuation of SAR448272 ProgramFintel · 6 days ago
- Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesZacks · Oct 22, 2026
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Zacks · Oct 19, 2026
- Nurix Swings To Profit In Q3 As Roche Deal Drives Revenue Surge RTTNews · Oct 13, 2026
- Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue RTTNews · Oct 13, 2026
- Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesZacks · Oct 12, 2026
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data RTTNews · Oct 9, 2026
The company
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix's clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix's autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and a clinical-stage degrader of IRAK4 in collaboration with Gilead. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- nurixtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.